FindTrial
Sign In

A cohort study of proteinuria selectivity index predicting the efficacy of rituximab in the treatment of primary nephrotic syndrome

A cohort study of proteinuria selectivity index predicting the efficacy of rituximab in the treatment of primary nephrotic syndrome

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082178
Enrollment
Unknown
Registered
2024-03-22
Start date
2024-03-22
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary nephrotic syndrome

Interventions

Selective proteinuria group
:None
Non-selective proteinuria group:None

Sponsors

Shenzhen Second People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Between 18 and 80 years old ? Patients with primary nephrotic syndrome who have undergone renal biopsy ? Has not been treated with rituximab ? Both blood and urine samples

Exclusion criteria

Exclusion criteria: ? Suspected patients with secondary nephrotic syndrome ? Hypersensitivity to active substances, murine proteins or excipients ? Severe active infection ? Patients with severely impaired immune function ? Severe heart failure or uncontrolled severe heart disease ?May affect the safety and efficacy assessment of this study and exclude patients who do not qualify as participants in this study

Design outcomes

Primary

MeasureTime frame
Proteinuria selectivity index;UPCR;Complete remission rate;—

Countries

China

Contacts

Public ContactQijun Wan

Shenzhen Second People’s Hospital

yiyuan2224@sina.com+86 135 3785 7368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026